Shadomy S, Dixon D M, Espinel-Ingroff A, Wagner G E, Yu H P, Shadomy H J
Antimicrob Agents Chemother. 1978 Jul;14(1):99-104. doi: 10.1128/AAC.14.1.99.
The in vitro antifungal inhibitory activities of ambruticin and of various antifungal drugs of choice against 190 fungal pathogens representative of the major human mycoses were compared using a modification of the ICS agar dilution technique. Ambruticin compared favorably with amphotericin B and miconazole when tested against the dimorphic pathogens Coccidioides immitis, Histoplasma capsulatum, and Blastomyces dermatitidis and against Aspergillus fumigatus. Miconazole was the most active compound against Sporothrix schenckii, Allescheria (Petriellidium) boydii, and selected dematiaceous fungi, with ambruticin giving minimal inhibitory, concentrations from 3- to 74-fold higher. Ambruticin compared unfavorably with amphotericin B and 5-fluorocytosine when tested against Candida and Torulopsis species. Ambruticin was not as active in vitro as tolnaftate when tested against the three genera of dermatophytic fungi, but compared favorably with miconazole.
采用改良的ICS琼脂稀释技术，比较了安布霉素及各种抗真菌常用药对190种代表主要人类真菌病的真菌病原体的体外抗真菌抑制活性。在针对双相病原体粗球孢子菌、荚膜组织胞浆菌、皮炎芽生菌以及烟曲霉进行测试时，安布霉素与两性霉素B和咪康唑效果相当。咪康唑是针对申克孢子丝菌、博伊德阿利什霉（佩特里盘菌属）及某些暗色真菌最具活性的化合物，而安布霉素的最低抑菌浓度要高出3至74倍。在针对念珠菌属和球拟酵母菌属进行测试时，安布霉素与两性霉素B和5-氟胞嘧啶相比效果不佳。在针对三个皮肤癣菌属进行测试时，安布霉素的体外活性不如托萘酯，但与咪康唑相比效果较好。
